Update on Guidelines for the Management of Cancer-Associated Thrombosis
Tóm tắt
Cancer-associated thrombosis (CAT) is a major cause of morbidity and mortality in patients with cancer. Over the past 2 decades, enormous advances have been made in the management of CAT. The growing evidence base informing practice has led to the publication of a number of guidelines and guidance documents on the diagnosis and treatment of CAT. The goal of this review is to examine the latest versions of evidence-based guidelines, highlighting the differences and similarities in their methodology, their disease-specific content, and recommendations for management. Our analysis shows that for most clinical topics, the different guidelines provide roughly similar management advice. However, there are a number of important clinical topics in CAT that are not currently covered by the existing guidelines. We think inclusion of these topics in future versions of the guidelines will facilitate ongoing efforts to optimize the care of patients with CAT.
Cancer-associated thrombosis (CAT) is a common complication in patients with cancer. This review examines the differences and similarities of the current CAT guidelines methods and recommendations. Current guidelines largely agree on many aspects of CAT management. However, there are a number of topics in CAT that are not currently included in guidelines where evidence-based guidance would be very helpful for clinicians. Coverage of these topics in future guidelines is encouraged to optimize clinical practice.
Từ khóa
Tài liệu tham khảo
Streiff, 2016, Thrombosis in the setting of cancer, Hematology Am Soc Hematol Educ Program, 1, 196, 10.1182/asheducation-2016.1.196
Wagman, 2006, Venous thromboembolic disease. Clinical practice guidelines in oncology, J Natl Compr Canc Netw, 4, 838, 10.6004/jnccn.2006.0071
Mandala, 2006, Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM), Crit Rev Oncol Hematol, 59, 194, 10.1016/j.critrevonc.2006.05.001
Lyman, 2007, American society of clinical oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer, J Clin Oncol, 25, 5490, 10.1200/JCO.2007.14.1283
Debourdeau, 2009, 2008 SOR guidelines for the prevention and treatment of thrombosis associated with central venous catheters in patients with cancer: Report from the working group, Ann Oncol, 20, 1459, 10.1093/annonc/mdp052
Key, 2020, Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update, J Clin Oncol, 38, 496, 10.1200/JCO.19.01461
Di Nisio, 2014, Subcommittee on Haemostasis and Malignancy. Prevention of venous thromboembolism in hospitalized medical cancer patients: Guidance from the SSC of the ISTH, J Thromb Haemost, 12, 1746, 10.1111/jth.12683
Wang, 2019, The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH, J Thromb Haemost, 17, 1772, 10.1111/jth.14564
Carrier, 2013, Subcommittee on Haemostasis and Malignancy for the SSC of the ISTH. Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: Guidance from the SSC of the ISTH, J Thromb Haemost, 11, 1760, 10.1111/jth.12338
Farge, 2019, 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, Lancet Oncol, 20, e566, 10.1016/S1470-2045(19)30336-5
NCCN, 2020
Munoz Martin, 2020, SEOM clinical guideline of venous thromboembolism (VTE) and cancer (2019), Clin Transl Oncol, 22, 171, 10.1007/s12094-019-02263-z
Carrier, 2014, Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer, Am J Med, 127, 82, 10.1016/j.amjmed.2013.09.015
Kroger, 2006, Risk factors for venous thromboembolic events in cancer patients, Ann Oncol, 17, 297, 10.1093/annonc/mdj068
Gerber, 2008, The incidence of and risk factors for venous thromboembolism (VTE) and bleeding among 1,514 patients undergoing hematopoietic stem cell transplantation: Implications for VTE prevention, Blood, 112, 504, 10.1182/blood-2007-10-117051
Connors, 2014, Prophylaxis against venous thromboembolism in patients with cancer, N Engl J Med, 371, 1263
Agnelli, 2009, Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: A randomised, placebo-controlled, double-blind study, Lancet Oncol, 10, 943, 10.1016/S1470-2045(09)70232-3
Agnelli, 2012, Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer, N Engl J Med, 366, 601, 10.1056/NEJMoa1108898
Khorana, 2008, Development and validation of a predictive model for chemotherapy-associated thrombosis, Blood, 111, 4902, 10.1182/blood-2007-10-116327
Carrier, 2019, Apixaban to prevent venous thromboembolism in patients with cancer, N Engl J Med, 380, 711, 10.1056/NEJMoa1814468
Khorana, 2019, Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer, N Engl J Med, 380, 720, 10.1056/NEJMoa1814630
Li, 2017, Cardiovascular and thrombotic complications of novel multiple myeloma therapies: A review, JAMA Oncol, 3, 980, 10.1001/jamaoncol.2016.3350
Li, 2019, Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma, J Natl Compr Canc Netw, 17, 840, 10.6004/jnccn.2018.7273
Sanfilippo, 2019, Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score, Am J Hematol, 94, 1176, 10.1002/ajh.25603
ENOXACAN Study Group, 1997, Efficacy and safety of enoxaparin versus unfractionated heparin for prevention of deep vein thrombosis in elective cancer surgery: A double-blind randomized multicentre trial with venographic assessment, Br J Surg, 84, 1099, 10.1002/bjs.1800840817
Bergqvist, 2002, Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer, N Engl J Med, 346, 975, 10.1056/NEJMoa012385
Rasmussen, 2006, Prolonged prophylaxis with dalteparin to prevent late thromboembolic complications in patients undergoing major abdominal surgery: A multicenter randomized open-label study, J Thromb Haemost, 4, 2384, 10.1111/j.1538-7836.2006.02153.x
Raskob, 2018, Edoxaban for the treatment of cancer-associated venous thromboembolism, N Engl J Med, 378, 615, 10.1056/NEJMoa1711948
Young, 2018, Comparison of an oral factor Xa Inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: Results of a randomized trial (SELECT-D), J Clin Oncol, 36, 2017, 10.1200/JCO.2018.78.8034
McBane, 2020, Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial, J Thromb Haemost, 18, 411, 10.1111/jth.14662
Agnelli, 2020, Apixaban for the treatment of venous thromboembolism associated with cancer, N Engl J Med, 382, 1599, 10.1056/NEJMoa1915103
Khorana, 2018, Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: Guidance from the SSC of the ISTH, J Thromb Haemost, 16, 1891, 10.1111/jth.14219
Kearon, 2016, Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report, Chest, 149, 315, 10.1016/j.chest.2015.11.026
Siontis, 2018, Outcomes associated with apixaban use in patients with end-stage kidney disease and atrial fibrillation in the United States, Circulation, 138, 1519, 10.1161/CIRCULATIONAHA.118.035418
Spyropoulos, 2019, Rivaroxaban versus warfarin treatment among morbidly obese patients with venous thromboembolism: Comparative effectiveness, safety, and costs, Thromb Res, 182, 159, 10.1016/j.thromres.2019.08.021
Hakeam, 2017, Effect of major gastrointestinal tract surgery on the absorption and efficacy of direct acting oral anticoagulants (DOACs), J Thromb Thrombolysis, 43, 343, 10.1007/s11239-016-1465-x
Siegal, 2013, Acute management of bleeding in patients on novel oral anticoagulants, Eur Heart J, 34, 489, 10.1093/eurheartj/ehs408
Geldhof, 2014, Venous thromboembolism in the elderly: Efficacy and safety of non-VKA oral anticoagulants, Thromb J, 12, 21, 10.1186/1477-9560-12-21
EINSTEIN Investigators, 2010, Oral rivaroxaban for symptomatic venous thromboembolism, N Engl J Med, 363, 2499, 10.1056/NEJMoa1007903
EINSTEIN-PE Investigators, 2012, Oral rivaroxaban for the treatment of symptomatic pulmonary embolism, N Engl J Med, 366, 1287, 10.1056/NEJMoa1113572
Schulman, 2009, RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism, N Engl J Med, 361, 2342, 10.1056/NEJMoa0906598
Schulman, 2014, RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis, Circulation, 129, 764, 10.1161/CIRCULATIONAHA.113.004450
Hokusai-VTE Investigators, 2013, Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism, N Engl J Med, 369, 1406, 10.1056/NEJMoa1306638
Agnelli, 2013, AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism, N Engl J Med, 369, 799, 10.1056/NEJMoa1302507
Samuelson Bannow, 2018, Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH, J Thromb Haemost, 16, 1246, 10.1111/jth.14015
Navi, 2017, Risk of arterial thromboembolism in patients with cancer, J Am Coll Cardiol, 70, 926, 10.1016/j.jacc.2017.06.047
Grilz, 2018, Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer, Haematologica, 103, 1549, 10.3324/haematol.2018.192419
Di Nisio, 2011, Arterial thrombosis in ambulatory cancer patients treated with chemotherapy, Thromb Res, 127, 382, 10.1016/j.thromres.2010.10.001
Brenner, 2018, RIETE Investigators. Arterial ischemic events are a major complication in cancer patients with venous thromboembolism, Am J Med, 131, 1095, 10.1016/j.amjmed.2018.04.037
Khorana, 2006, Thromboembolism in hospitalized neutropenic cancer patients, J Clin Oncol, 24, 484, 10.1200/JCO.2005.03.8877
Zoller, 2012, Risk of haemorrhagic and ischaemic stroke in patients with cancer: A nationwide follow-up study from Sweden, Eur J Cancer, 48, 1875, 10.1016/j.ejca.2012.01.005